Literature DB >> 16644654

Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose.

Muhammad A Abdul-Ghani1, Devjit Tripathy, Ralph A DeFronzo.   

Abstract

Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are intermediate states in glucose metabolism that exist between normal glucose tolerance and overt diabetes. Epidemiological studies demonstrate that the two categories describe distinct populations with only partial overlap, suggesting that different metabolic abnormalities characterize IGT and IFG. Insulin resistance and impaired beta-cell function, the primary defects observed in type 2 diabetes, both can be detected in subjects with IGT and IFG. However, clinical studies suggest that the site of insulin resistance varies between the two disorders. While subjects with IGT have marked muscle insulin resistance with only mild hepatic insulin resistance, subjects with IFG have severe hepatic insulin resistance with normal or near-normal muscle insulin sensitivity. Both IFG and IGT are characterized by a reduction in early-phase insulin secretion, while subjects with IGT also have impaired late-phase insulin secretion. The distinct metabolic features present in subjects with IFG and IGT may require different therapeutic interventions to prevent their progression to type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644654     DOI: 10.2337/diacare.2951130

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  266 in total

Review 1.  The emergence of sedentary behaviour physiology and its effects on the cardiometabolic profile in young and older adults.

Authors:  D J Ryan; G K Stebbings; G L Onambele
Journal:  Age (Dordr)       Date:  2015-08-28

Review 2.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

3.  Strategies for preventing type 2 diabetes: an update for clinicians.

Authors:  Kaivan Khavandi; Halima Amer; Bashar Ibrahim; Jack Brownrigg
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

Review 4.  Diabetes prevention: can insulin secretagogues do the job?

Authors:  Barbara Westerhaus; Aidar R Gosmanov; Guillermo E Umpierrez
Journal:  Prim Care Diabetes       Date:  2010-12-24       Impact factor: 2.459

5.  Assessing the risk of impaired glucose metabolism in overweight adolescents in a clinical setting.

Authors:  P A Velasquez-Mieyer; P A Cowan; C P Neira; F Tylavsky
Journal:  J Nutr Health Aging       Date:  2008-12       Impact factor: 4.075

Review 6.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

7.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Authors:  R A DeFronzo; M A Banerji; G A Bray; T A Buchanan; S Clement; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R Ratner; P Reaven; D C Schwenke; F D Stentz; D Tripathy
Journal:  Diabetologia       Date:  2009-12-10       Impact factor: 10.122

8.  Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study.

Authors:  Carlos Lorenzo; Sara Hartnett; Anthony J Hanley; Marian J Rewers; Lynne E Wagenknecht; Andrew J Karter; Steven M Haffner
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

9.  Extracts of Rehmanniae radix, Ginseng radix and Scutellariae radix improve glucose-stimulated insulin secretion and beta-cell proliferation through IRS2 induction.

Authors:  Sun Min Park; Sang Mee Hong; So Ra Sung; Ji Eun Lee; Dae Young Kwon
Journal:  Genes Nutr       Date:  2008-02       Impact factor: 5.523

10.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

Authors:  Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.